Director-linked entity buys Zivo Bioscience (ZIVO) shares in open market

Rhea-AI Filing Summary

Zivo Bioscience insider reporting shows an indirect open-market purchase of common stock tied to director and 10% owner Laith L. Yaldoo. On 02/10/2026, HEP Investments LLC, an entity associated with Yaldoo, bought 2,434 shares of Zivo Bioscience common stock at $10.27 per share. Following this transaction, HEP Investments LLC indirectly held 582,072 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YALDOO LAITH L

(Last) (First) (Middle)

1934 BLOOMFIELD ROAD

(Street)

BLOOMFIELD HILLS MI 48302

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		P		2,434	A	$10.27	582,072	I	HEP Investments LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Laith L. Yaldoo	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zivo Bioscience (ZIVO) report for Laith L. Yaldoo?

Zivo Bioscience reported an indirect insider purchase linked to director and 10% owner Laith L. Yaldoo. On 02/10/2026, HEP Investments LLC, an entity associated with him, acquired 2,434 common shares in an open-market transaction at $10.27 per share.

How many Zivo Bioscience (ZIVO) shares were bought in the latest Form 4 filing?

The Form 4 shows that 2,434 Zivo Bioscience common shares were purchased. The transaction occurred on 02/10/2026 at a price of $10.27 per share through HEP Investments LLC, which is reported as indirectly holding the position.

At what price were Zivo Bioscience (ZIVO) shares purchased in this insider trade?

The reported insider trade lists a purchase price of $10.27 per Zivo Bioscience common share. This price applied to 2,434 shares bought on 02/10/2026 by HEP Investments LLC, which is shown as indirectly owned by Laith L. Yaldoo.

How many Zivo Bioscience (ZIVO) shares are indirectly owned after the reported transaction?

After the transaction, HEP Investments LLC is reported as indirectly owning 582,072 Zivo Bioscience common shares. This total reflects the addition of 2,434 shares acquired on 02/10/2026 in an open-market purchase at $10.27 per share.

Is the recent Zivo Bioscience (ZIVO) insider transaction a buy or a sell?

The recent insider transaction is a buy. The Form 4 identifies transaction code "P" for a purchase, showing HEP Investments LLC acquiring 2,434 Zivo Bioscience common shares on 02/10/2026 at $10.27 per share in an open-market transaction.